Table S1.

Ongoing clinical trials of early treatment in SMM patients

NCT number	Design	Arm(s)	N	Participants	Current status	Expected date
NCT02916771	Phase II single-arm	Ixazomib+LD	28	High-risk	Recruiting	2020-04
NCT02903381	Phase II single-arm	Nivolumab+LD	41	High-risk	Suspended	2020-06
NCT02279394	Phase II single-arm	Elotuzumab+LD	51	High-risk	Active	2020-01
NCT03301220	Phase III RCT	Daratumumab SC vs monitoring	360	High-risk	Recruiting	2021-12
NCT02415413	Phase II single-arm	Carfilzomib+LD	90	High-risk	Active	2020-05
NCT02943473	Phase II single-arm	Ibrutinib	36	High-risk	Recruiting	2023-12
NCT01484275	Phase II RCT	Siltuximab vs placebo	87	High-risk	Active	2019-08
NCT03236428	Phase II single-arm	Daratumumab	40	Low-risk	Recruiting	2020-08
NCT02697383	Phase I single-arm	Ixazomib+D	14	High-risk	Active	2019-02
NCT03289299	Phase II single-arm	Carfilzomib+Daratumumab+LD	83	High-risk	Recruiting	2022-06
NCT02886065	Phase I controlled	PVX-410+Citarinostat vs PVX-410+Citarinostat+L	20	High-risk	Recruiting	2021-05
NCT02603887	Phase I single-arm	Pembrolizumab	13	Intermediate- and high-risk	Active	2020-07
NCT01169337	Phase II/III RCT	L vs observation	180	High-risk	Active	2020-03
NCT03631043	Phase I single-arm	Personalized vaccine	30	Intermediate- and high-risk	Not yet recruiting	2022-09
NCT02784483	Phase I single-arm	Atezolizumab	20	High-risk	Suspended	2018-12
NCT03673826	Phase II RCT	Carfilzomib+LD vs LD	120	High-risk	Not yet recruiting	2025-10
NCT02960555	Phase II single-arm	Isatuximab	61	High-risk	Recruiting	2022-02
NCT01572480	Phase II single-arm	Carfilzomib+LD	53	High-risk	Recruiting	2022-06
NCT03591614	Phase I single-arm	DKK1 vaccine	18	NA	Not yet recruiting	2019-08
NCT02492750	Phase I/II RCT	LD+anakinra vs LD+placebo	120	High-risk	Suspended	2020-07

Abbreviations: SMM, smoldering multiple myeloma; L, lenalidomide; D, dexamethasone; RCT, randomized controlled trial.